The International Linked Clinical Trials (iLCT) programme is the flagship drug repurposing initiative of Cure Parkinson’s and Van Andel Institute (VAI) focussed on identifying and clinically testing already available drugs that show potential to slow, stop or reverse the progression of Parkinson’s.

Every year the iLCT committee, of over 20 Parkinson’s specialists, meets to discuss the progress of current iLCT clinical trials and importantly, debates a set of newly collated dossiers outlining current medical knowledge on a range of novel treatments which show potential for Parkinson’s. Once drugs are prioritised by the committee, Cure Parkinson’s is mandated to then take them into clinical trials. 

comorbidities of epilepsy

The pandemic has meant that the recent iLCT meetings have been virtual, however this has not diminished the determination and enthusiasm of the committee members to progress their objectives. The committee met in October and prioritised new drug candidates to move to clinical trials.

Approximately half of the dossiers assessed at the recent meeting were of novel therapeutics that are being developed by biotech companies (under strict non-disclosure conditions) . The remainder focused on molecules that offer potential to be repurposed in clinical trials for Parkinson’s.

In summary, five agents were prioritised by the committee at this iLCT meeting; Cure Parkinson’s will now focus all effort into advancing each of these into clinical testing.

Here, Dr Simon Stott presents his 2021 update on current iLCT trials and those about to begin.